Mansi Rosalba, Bertarelli Natalie, Del Pozzo Luigi, Zanger Sandra, Basaco Bernabeu Tais, Maecke Helmut, Fani Melpomeni
Division of Radiopharmaceutical Chemistry, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
EJNMMI Radiopharm Chem. 2025 Jul 1;10(1):35. doi: 10.1186/s41181-025-00363-6.
The radiolabeled somatostatin receptor subtype 2 (SST) antagonists LM3 (Phe(4-Cl)-c(DCys-Tyr-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH) and JR11 (Phe(4-Cl)-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH) are under clinical evaluation for imaging and treatment of neuroendocrine tumors. These peptides differ at position 3, where LM3 contains Tyr, while JR11 incorporates Aph(Hor). The amino acid at this position is crucial in the design of somatostatin ligands, agonists and antagonists, influencing affinity and receptor subtype specificity. Pyridylalanine, a nonnatural amino acid, presents three regioisomers 2-pyridylalanine (2Pal), 3-pyridylalanine (3Pal), and 4-pyridylalanine (4Pal), which differ only in the nitrogen atom's position in the aromatic ring, allowing minimal chemical modification. We investigated whether the new somatostatin antagonists DOTA-[2Pal]-LM3, DOTA-[3Pal]-LM3 and DOTA-[4Pal]-LM3, radiolabeled with Lu-177, differ among them and how they compare with the clinically used [Lu]Lu-DOTA-LM3.
The synthesis of the DOTA-[2Pal]-LM3 resulted in the formation of two diastereomers, with the D2Pal derivative lacking receptor recognition and affinity, contrary to the enantiomer L (L2Pal) derivative. The hydrophilicity of [Lu]Lu-DOTA-[xPal]-LM3 increased in the order of L2Pal < 3Pal < 4Pal (logD = -2.3 ± 0.1 -2.5 ± 0.1 and -2.6 ± 0.1, respectively), being similar or significantly higher than [Lu]Lu-DOTA-LM3 (logD = -2.3 ± 0.1). Saturation binding studies indicated a trend of affinity improvement by L2Pal < 3Pal < 4Pal (K = 0.18 ± 0.02, 0.15 ± 0.01 and 0.11 ± 0.01 nM, respectively), which is similar to [Lu]Lu-DOTA-LM3 (K = 0.09 ± 0.02 nM). Surprisingly, despite similar accumulation in SST-positive tumors, differences were observed in the body distribution. The hydrophilicity of the Pal amino acids is likely responsible for the higher kidney uptake of the three Lu-Pal-radioligands when compared to [Lu]Lu-DOTA-LM3. In particular, [Lu]Lu-DOTA-[3Pal]-LM3 is characterized by high uptake and long retention in kidneys, probably due to its high stability in renal tissue. Chromatographic analysis of kidney homogenates revealed that more than 60% of peptide remained intact 1 h after injection.
Our study revealed that the replacement of Tyr with Pal isomers does not impact on SST affinity, but chirality at this position is critical, as the D2Pal derivative loses binding. More interestingly, we demonstrated how the nitrogen's position in the pyridylalanine regioisomers influences the properties of the corresponding radioligand. The polar nature of the 3Pal, due to its electronic density dissymmetry, likely enhances the peptide interaction with specific kidney transporters explaining its high uptake and prolonged retention in renal tissue.
放射性标记的生长抑素受体2型(SST)拮抗剂LM3(Phe(4-Cl)-c(DCys-Tyr-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH)和JR11(Phe(4-Cl)-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH)正在进行神经内分泌肿瘤成像和治疗的临床评估。这些肽在第3位不同,其中LM3含有酪氨酸,而JR11含有Aph(Hor)。该位置的氨基酸在生长抑素配体、激动剂和拮抗剂的设计中至关重要,会影响亲和力和受体亚型特异性。吡啶基丙氨酸是一种非天然氨基酸,有三种区域异构体,即2-吡啶基丙氨酸(2Pal)、3-吡啶基丙氨酸(3Pal)和4-吡啶基丙氨酸(4Pal),它们仅在芳环中氮原子的位置不同,允许进行最小程度的化学修饰。我们研究了用镥-177放射性标记的新型生长抑素拮抗剂DOTA-[2Pal]-LM3、DOTA-[3Pal]-LM3和DOTA-[4Pal]-LM3之间是否存在差异,以及它们与临床使用的[镥]镥-DOTA-LM3相比如何。
DOTA-[2Pal]-LM3的合成产生了两种非对映异构体,与对映体L(L2Pal)衍生物相反,D2Pal衍生物缺乏受体识别和亲和力。[镥]镥-DOTA-[xPal]-LM3的亲水性按L2Pal<3Pal<4Pal的顺序增加(logD分别为-2.3±0.1、-2.5±0.1和-2.6±0.1),与[镥]镥-DOTA-LM3(logD = -2.3±0.1)相似或显著更高。饱和结合研究表明亲和力有L2Pal<3Pal<4Pal的改善趋势(K分别为0.18±0.02、0.15±0.01和0.11±0.01 nM),这与[镥]镥-DOTA-LM3(K = 0.09±0.02 nM)相似。令人惊讶的是,尽管在SST阳性肿瘤中的积累相似,但在体内分布上观察到了差异。与[镥]镥-DOTA-LM3相比,Pal氨基酸的亲水性可能是三种镥-Pal放射性配体肾脏摄取更高的原因。特别是,[镥]镥-DOTA-[3Pal]-LM3的特点是在肾脏中摄取高且滞留时间长,这可能是由于其在肾组织中的高稳定性。肾脏匀浆的色谱分析显示,注射后1小时超过60%的肽保持完整。
我们的研究表明,用Pal异构体替代酪氨酸不会影响SST亲和力,但该位置的手性至关重要,因为D2Pal衍生物失去了结合能力。更有趣的是,我们证明了吡啶基丙氨酸区域异构体中氮的位置如何影响相应放射性配体的性质。3Pal的极性性质,由于其电子密度不对称,可能增强了肽与特定肾脏转运体的相互作用,解释了其在肾组织中的高摄取和长时间滞留。